Scott E Counts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8546672/publications.pdf

Version: 2024-02-01

84 papers 5,631 citations

39 h-index 72 g-index

86 all docs

86 docs citations

86 times ranked 7063 citing authors

#	Article	IF	CITATIONS
1	Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers. Molecular Psychiatry, 2022, 27, 1256-1273.	7.9	26
2	Co-expression network analysis of frontal cortex during the progression of Alzheimer's disease. Cerebral Cortex, 2022, 32, 5108-5120.	2.9	4
3	Anti-fibrillization effects of sulfonamide derivatives on α-synuclein and hyperphosphorylated tau isoform 1N4R. Journal of Molecular Structure, 2022, 1267, 133574.	3.6	6
4	Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders. Brain Communications, 2022, 4, .	3.3	10
5	MicroRNA-298 reduces levels of human amyloid- \hat{l}^2 precursor protein (APP), \hat{l}^2 -site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Molecular Psychiatry, 2021, 26, 5636-5657.	7.9	61
6	Pontine Arteriolosclerosis and Locus Coeruleus Oxidative Stress Differentiate Resilience from Mild Cognitive Impairment in a Clinical Pathologic Cohort. Journal of Neuropathology and Experimental Neurology, 2021, 80, 325-335.	1.7	7
7	Alteration of a specific microRNA regulating neprilysin expression in Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e054693.	0.8	O
8	Sex differences in the therapeutic efficacy of oxytocin receptor signaling in a rat model of vascular cognitive impairment Alzheimer's and Dementia, 2021, 17 Suppl 3, e055561.	0.8	0
9	Oxytocin Receptor Signaling in Vascular Function and Stroke. Frontiers in Neuroscience, 2020, 14, 574499.	2.8	17
10	Therapeutic potential of oxytocin receptor signaling in vascular dementia. Alzheimer's and Dementia, 2020, 16, e045493.	0.8	1
11	Dysfunctional neuroplasticity in newly arrived Middle Eastern refugees in the U.S.: Association with environmental exposures and mental health symptoms. PLoS ONE, 2020, 15, e0230030.	2.5	8
12	Title is missing!. , 2020, 15, e0230030.		O
13	Title is missing!. , 2020, 15, e0230030.		O
14	Title is missing!. , 2020, 15, e0230030.		0
15	Title is missing!. , 2020, 15, e0230030.		O
16	Nerve Growth Factor Pathobiology During the Progression of Alzheimer's Disease. Frontiers in Neuroscience, 2019, 13, 533.	2.8	60
17	Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology. Neurobiology of Disease, 2019, 132, 104540.	4.4	32
18	Locus Coeruleus Degeneration Induces Forebrain Vascular Pathology in a Transgenic Rat Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 371-388.	2.6	26

#	Article	IF	CITATIONS
19	Peri-Infarct Upregulation of the Oxytocin Receptor in Vascular Dementia. Journal of Neuropathology and Experimental Neurology, 2019, 78, 436-452.	1.7	56
20	Response to Letter to the Editor "Biomarkers Determination of the Nurse in Various Work Environmentsâ€. Journal of Occupational and Environmental Medicine, 2019, 61, e535.	1.7	0
21	Nurse Work Environment and Stress Biomarkers. Journal of Occupational and Environmental Medicine, 2019, 61, 676-681.	1.7	24
22	Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease. Hippocampus, 2019, 29, 422-439.	1.9	45
23	Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 246-259.	1.7	31
24	Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 1086-1095.	1.4	8
25	Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiology of Disease, 2018, 117, 125-136.	4.4	37
26	Alzheimerâ∈™s Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. Journal of Alzheimer's Disease, 2017, 58, 979-992.	2.6	70
27	Multi-Infarct Dementia: A Historical Perspective. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 160-171.	1.3	14
28	Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Acta Neuropathologica Communications, 2017, 5, 8.	5.2	197
29	Regulator of Cell Cycle (RGCC) Expression during the Progression of Alzheimer's Disease. Cell Transplantation, 2017, 26, 693-702.	2.5	41
30	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics, 2017, 14, 35-53.	4.4	128
31	[P2–179]: MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE (MTUPR) DYSFUNCTION DURING THE PROGRESSION OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P674.	0.8	2
32	Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature, 2017, 552, 187-193.	27.8	471
33	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioural Brain Research, 2016, 311, 54-69.	2.2	99
34	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiology of Aging, 2016, 42, 80-90.	3.1	25
35	Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. Experimental Neurology, 2016, 283, 318-329.	4.1	28
36	Evidence for Mitochondrial UPR Gene Activation in Familial and Sporadic Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 610-614.	1.4	91

SCOTT E COUNTS

#	Article	IF	Citations
37	Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 800-808.	1.4	35
38	Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Frontiers in Neuroscience, 2015, 9, 430.	2.8	64
39	Editorial (Thematic Issue: Overview of Immunotherapy in Alzheimer's Disease (AD) and Mechanisms of) Tj ETo	Qq1 _{1.4} 1 0.7	84314 rgBT
40	Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology, 2014, 79, 172-179.	4.1	109
41	Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer's Disease. Journal of Clinical Immunology, 2014, 34, 80-85.	3.8	21
42	Intravenous Immunoglobulin Reduces Tau Pathology and Preserves Neuroplastic Gene Expression in the 3xTg Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 655-663.	1.4	14
43	Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 216-219.	1.4	75
44	Hippocampal ProNGF Signaling Pathways and \hat{l}^2 -Amyloid Levels in Mild Cognitive Impairment and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1018-1029.	1.7	89
45	Rac1b Increases with Progressive Tau Pathology within Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease. American Journal of Pathology, 2012, 180, 526-540.	3.8	30
46	Locus Coeruleus. , 2012, , 425-438.		28
47	Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 13-30.	7.7	189
48	Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. International Journal of Physiology, Pathophysiology and Pharmacology, 2012, 4, 115-27.	0.8	17
49	Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 111-117.	2.1	31
50	Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 102-110.	2.1	107
51	DHA diet reduces AD pathology in young APPswe/PS1î"E9 transgenic mice: Possible gender effects. Journal of Neuroscience Research, 2010, 88, 1026-1040.	2.9	81
52	Regional Selectivity of rab5 and rab7 Protein Upregulation in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 631-639.	2.6	110
53	Putative CSF protein biomarker candidates for amnestic mild cognitive impairment. Translational Neuroscience, 2010, 1, 2-8.	1.4	12
54	Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. Journal of Neurochemistry, 2010, 113, 649-660.	3.9	130

#	Article	IF	Citations
55	Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression. Biological Psychiatry, 2010, 68, 885-893.	1.3	229
56	Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neuroscience Letters, 2010, 471, 129-133.	2.1	40
57	Neuroprotective Role for Galanin in Alzheimer's Disease. Exs, 2010, 102, 143-162.	1.4	37
58	Cortical $\hat{l}\pm7$ Nicotinic Acetylcholine Receptor and \hat{l}^2 -Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 2009, 66, 646-51.	4.5	59
59	Galanin Fiber Hyperinnervation Preserves Neuroprotective Gene Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 885-896.	2.6	53
60	The regulation of presenilin-1 by nerve growth factor. Journal of Neurochemistry, 2008, 76, 679-689.	3.9	11
61	Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Review of Neurotherapeutics, 2008, 8, 1703-1718.	2.8	493
62	Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Neurodegenerative Diseases, 2008, 5, 228-231.	1.4	33
63	Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly. Current Alzheimer Research, 2007, 4, 340-350.	1.4	91
64	$\hat{l}\pm7$ Nicotinic Receptor Up-regulation in Cholinergic Basal Forebrain Neurons in Alzheimer Disease. Archives of Neurology, 2007, 64, 1771.	4.5	103
65	Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Research, 2007, 1134, 33-44.	2.2	12
66	Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Progress in Brain Research, 2006, 158, 197-222.	1.4	42
67	Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 1401-1408.	3.9	93
68	Down regulation of trk but not p75 ^{NTR} gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. Journal of Neurochemistry, 2006, 97, 475-487.	3.9	229
69	Single cell gene expression profiling in Alzheimer's disease. NeuroRx, 2006, 3, 302-318.	6.0	71
70	Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 592-601.	1.7	183
71	Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 205-214.	1.5	40
72	Single cell gene expression profiling in Alzheimer's disease. Neurotherapeutics, 2006, 3, 302-318.	4.4	O

SCOTT E COUNTS

#	Article	IF	CITATION
73	RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. Journal of Neuroscience Methods, 2005, 144, 197-201.	2.5	2
74	Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice. Neuropeptides, 2005, 39, 233-237.	2.2	33
75	The Role of Nerve Growth Factor Receptors in Cholinergic Basal Forebrain Degeneration in Prodromal Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 263-272.	1.7	210
76	Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders. Neurochemical Research, 2004, 29, 1053-1064.	3.3	84
77	Reduction of cortical TrkA but not p75 ^{NTR} protein in earlyâ€stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	5.3	181
78	Preservation of Brain Nerve Growth Factor in Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2003, 60, 1143.	4.5	65
79	Galanin in Alzheimer Disease. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 137-156.	3.4	56
80	Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons. Journal of Neurochemistry, 2002, 83, 442-451.	3.9	32
81	Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochemical Research, 2002, 27, 1035-1048.	3.3	141
82	Galanin: Neurobiologic Mechanisms and Therapeutic Potential for Alzheimer's Disease. CNS Neuroscience & Therapeutics, 2001, 7, 445-470.	4.0	45
83	Coordinate Expression of the Vesicular Acetylcholine Transporter and Choline Acetyltransferase Following Septohippocampal Pathway Lesions. Journal of Neurochemistry, 1998, 71, 2411-2420.	3.9	22
84	Light and Electron Microscopic Localization of Presenilin-1 in Primate Brain. Journal of Neuroscience, 1997, 17, 1971-1980.	3.6	158